Visualizing Progress in the Treatment of Chronic Active Antibody-Mediated Rejection: A Closer Look at the Clinical Potential of Targeting IL-6 to Improve Outcomes in the Kidney Transplant Setting
Visualizing Progress in the Treatment of Chronic Active Antibody-Mediated Rejection: A Closer Look at the Clinical Potential of Targeting IL-6 to Improve Outcomes in the Kidney Transplant Setting is organized by PVI, PeerView Institute for Medical Education.
Activity Release Date: May 11, 2023
Activity Expiration Date: May 10, 2024
Activity Description:
In this animated video activity, Dr. Stanley C. Jordan discusses the rationale for targeting IL-6 in chronic active antibody-mediated rejection, as well as the use of anti–IL-6 agents for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting.
Educational Objectives:
Upon completion of this activity, participants should be better able to:
• Utilize the Banff classification to characterize the nature and extent of kidney transplant rejection in order to guide treatment
• Discuss the rationale for targeting IL-6 as a therapeutic approach to chronic active antibody-mediated rejection in kidney transplant recipients
• Evaluate the efficacy, safety, and clinical potential of anti–IL-6 agents currently in development for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting.
